Clinical Trials

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02971501 2026-03-17

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

7 enrolled 9 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03381274 2026-03-11

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

43 enrolled 30 charts

Carcinoma, Non-Small-Cell Lung

NCT04285671 2026-03-10

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

30 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03521154 2026-02-27

LAURA

216 enrolled 25 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03940703 2026-02-27

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

140 enrolled 47 charts

Carcinoma, Non-Small-Cell Lung

NCT04606771 2026-02-27

CoC

30 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03778229 2026-02-10

SAVANNAH

367 enrolled 32 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-02-04

MARIPOSA

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05546866 2026-01-27

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

51 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05816252 2026-01-27

MK-2870-003

356 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03392246 2026-01-22

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04743505 2026-01-20

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

27 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02411448 2026-01-16

RELAY

545 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04765059 2026-01-13

COMPEL

98 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT04769388 2026-01-12

FLAME

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05120349 2026-01-12

ADAURA2

390 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03410043 2025-12-26

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

173 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05103605 2025-12-01

POSITHES

Active not recruiting

274 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03122717 2025-11-12

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03667820 2025-11-04

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

41 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03909334 2025-10-20

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

160 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04035486 2025-10-10

FLAURA2

587 enrolled 44 charts 1 FDA

Phase 2/3 Active not recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05020769 2025-09-26

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

14 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03831932 2025-09-19

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

22 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05880706 2025-09-19

A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

198 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04721015 2025-07-03

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

81 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04676477 2025-06-22

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

246 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05015608 2025-05-23

SACHI

250 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

423 enrolled

Phase NA Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03969823 2025-05-15

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

148 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06827145 2025-02-14

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03433469 2025-01-31

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

27 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03944772 2025-01-30

ORCHARD

247 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03769103 2024-10-31

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

40 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06391944 2024-04-30

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

161 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05163249 2024-02-09

FLOWERS

44 enrolled